This section describes the strategies to treat haematological disorders, especially AML by targeting intracellular RNA-modification machineries, like EEE (Editor/writer: Mettl3, Mettl14; Eraser/remover: FTO, ALKBH5 and Effector/reader: YTHDF-1, YTHDF-2) (Box 1), microRNAs and Suppressor of Cytokine Signalling family of proteins (SOCS/CISH) and describing how these can be developed as personalized medicines (Figure 1). Here, CISH is linked to acute myeloid leukemia.